Spero Therapeutics, Inc. Lease, Cost
Spero Therapeutics, Inc. (SPRO) reported Lease, Cost of $1.23 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-26
- Spero Therapeutics, Inc. lease, cost for the quarter ending 2020-12-31 was $425.00K, a 63.46% increase year-over-year.
- Spero Therapeutics, Inc. lease, cost for the quarter ending 2020-09-30 was $388.00K, a 16.38% decline year-over-year.
- Spero Therapeutics, Inc. lease, cost for the quarter ending 2020-06-30 was $284.00K, a 24.67% decline year-over-year.
- Spero Therapeutics, Inc. lease, cost for the quarter ending 2020-03-31 was $276.00K, a 26.79% decline year-over-year.
- Spero Therapeutics, Inc. lease, cost for fiscal 2025 was $1.23M, a 22.66% decline from fiscal 2024.
- Spero Therapeutics, Inc. lease, cost for fiscal 2024 was $1.58M, a 2.58% decline from fiscal 2023.
- Spero Therapeutics, Inc. lease, cost for fiscal 2023 was $1.63M, a 4.97% decline from fiscal 2022.
- Spero Therapeutics, Inc. lease, cost for fiscal 2022 was $1.71M, a 3.28% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.23M 10-K · filed 2026-03-26 | |||
| 2024-12-31 | $1.58M 10-K · filed 2026-03-26 | |||
| 2023-12-31 | $1.63M 10-K · filed 2025-03-27 | |||
| 2022-12-31 | $1.71M 10-K · filed 2024-03-13 | |||
| 2021-12-31 | $1.77M 10-K · filed 2023-03-30 | |||
| 2020-12-31 | $425.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $813.00K derived: sum of 2 quarters · filed 2022-03-31 | $1.10M derived: sum of 3 quarters · filed 2022-03-31 | $1.37M 10-K · filed 2022-03-31 |
| 2020-09-30 | $388.00K 10-Q · filed 2020-11-05 | $672.00K derived: sum of 2 quarters · filed 2020-11-05 | $948.00K 10-Q · filed 2020-11-05 | $1.21M derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-06-30 | $284.00K 10-Q · filed 2020-08-06 | $559.00K 10-Q · filed 2020-08-06 | $820.00K derived: sum of 3 quarters · filed 2021-03-11 | $1.28M derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-03-31 | $276.00K 10-Q · filed 2020-05-08 | $536.00K derived: sum of 2 quarters · filed 2021-03-11 | $1.00M derived: sum of 3 quarters · filed 2021-03-11 | $1.38M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-12-31 | $260.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $724.00K derived: sum of 2 quarters · filed 2021-03-11 | $1.10M derived: sum of 3 quarters · filed 2021-03-11 | $1.48M 10-K · filed 2021-03-11 |
| 2019-09-30 | $464.00K 10-Q · filed 2019-11-04 | $841.00K derived: sum of 2 quarters · filed 2019-11-04 | $1.22M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $377.00K 10-Q · filed 2019-08-08 | $754.00K 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $377.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |